niacinamide has been researched along with Myoepithelial Tumor in 1 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Excerpt | Relevance | Reference |
---|---|---|
"Sorafenib is the first anti-angiogenic agent to demonstrate activity in RMSGC patients, particularly in some histotypes such as HG-MEC, SDC and adenocarcinoma, NOS." | 5.22 | A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. ( Alfieri, S; Bergamini, C; Bossi, P; Civelli, E; Cortelazzi, B; Dagrada, GP; Granata, R; Imbimbo, M; Licitra, L; Lo Vullo, S; Locati, LD; Mariani, L; Mirabile, A; Morosi, C; Orlandi, E; Perrone, F; Pilotti, S; Quattrone, P; Resteghini, C; Saibene, G, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Locati, LD | 1 |
Perrone, F | 1 |
Cortelazzi, B | 1 |
Bergamini, C | 1 |
Bossi, P | 1 |
Civelli, E | 1 |
Morosi, C | 1 |
Lo Vullo, S | 1 |
Imbimbo, M | 1 |
Quattrone, P | 1 |
Dagrada, GP | 1 |
Granata, R | 1 |
Resteghini, C | 1 |
Mirabile, A | 1 |
Alfieri, S | 1 |
Orlandi, E | 1 |
Mariani, L | 1 |
Saibene, G | 1 |
Pilotti, S | 1 |
Licitra, L | 1 |
1 trial available for niacinamide and Myoepithelial Tumor
Article | Year |
---|---|
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepider | 2016 |